Abstract LB119: Precision combination therapies based on recurrent oncogenic co-alterations

Authors

• Anil Korkut, UT MD Anderson Cancer Center, Houston, TX
• Xubin Li, UT MD Anderson Cancer Center, Houston, TX
• Elizabeth Kong, UT MD Anderson Cancer Center, Houston, TX
• Gonghong Yan, UT MD Anderson Cancer Center, Houston, TX
• Zeynep Dereli, UT MD Anderson Cancer Center, Houston, TX
• Behnaz Bozorgui, UT MD Anderson Cancer Center, Houston, TX
• Parisa Imanirad, UT MD Anderson Cancer Center, Houston, TX
• Jacob Elnaggar, LSU Health Sciences Center - New OrleansFollow
• Augustin Luna, Dana-Farber Cancer institute, Boston, MA
• David G. Menter, UT MD Anderson Cancer Center, Houston, TX
• Patrick Pilie, UT MD Anderson Cancer Center, Houston, TX
• Timothy A. Yap, UT MD Anderson Cancer Center, Houston, TX
• Scott Kopetz, UT MD Anderson Cancer Center, Houston, TX
• Chris Sander, Harvard Medical School, Boston, MA

Document Type

Conference Proceeding

Publication Date

6-15-2022

Publication Title

Cancer Research

Abstract

Proceedings of the American Association for Cancer Research Annual Meeting 2022; Apr 8 - 13, 2022; Philadelphia, PA

Volume

82

Issue

12, Supplement

Publisher

American Association for Cancer Research

Comments

Abstract LB119

Rights

©2022 American Association for Cancer Research

Recommended Citation

Korkut, Anil; Li, Xubin; Kong, Elizabeth; Yan, Gonghong; Dereli, Zeynep; Bozorgui, Behnaz; Imanirad, Parisa; Elnaggar, Jacob; Luna, Augustin; Menter, David G.; Pilie, Patrick; Yap, Timothy A.; Kopetz, Scott; and Sander, Chris, "Abstract LB119: Precision combination therapies based on recurrent oncogenic co-alterations" (2022). School of Medicine Faculty Publications. 4522.
https://digitalscholar.lsuhsc.edu/som_facpubs/4522
10.1158/1538-7445.AM2022-LB119